dc.contributor.author | Robles-Zurita, J | |
dc.contributor.author | Boyd, KA | |
dc.contributor.author | Briggs, AH | |
dc.contributor.author | Iveson, T | |
dc.contributor.author | Kerr, RS | |
dc.contributor.author | Saunders, MP | |
dc.contributor.author | Cassidy, J | |
dc.contributor.author | Hollander, NH | |
dc.contributor.author | Tabernero, J | |
dc.contributor.author | Segelov, E | |
dc.contributor.author | Glimelius, B | |
dc.contributor.author | Harkin, A | |
dc.contributor.author | Allan, K | |
dc.contributor.author | McQueen, J | |
dc.contributor.author | Pearson, S | |
dc.contributor.author | Waterston, A | |
dc.contributor.author | Medley, L | |
dc.contributor.author | Wilson, C | |
dc.contributor.author | Ellis, R | |
dc.contributor.author | Essapen, S | |
dc.contributor.author | Dhadda, AS | |
dc.contributor.author | Hughes, R | |
dc.contributor.author | Falk, S | |
dc.contributor.author | Raouf, S | |
dc.contributor.author | Rees, C | |
dc.contributor.author | Olesen, RK | |
dc.contributor.author | Propper, D | |
dc.contributor.author | Bridgewater, J | |
dc.contributor.author | Azzabi, A | |
dc.contributor.author | Farrugia, D | |
dc.contributor.author | Webb, A | |
dc.contributor.author | Cunningham, D | |
dc.contributor.author | Hickish, T | |
dc.contributor.author | Weaver, A | |
dc.contributor.author | Gollins, S | |
dc.contributor.author | Wasan, HS | |
dc.contributor.author | Paul, J | |
dc.date.accessioned | 2019-02-20T07:50:45Z | |
dc.date.issued | 2018-11-13 | |
dc.identifier.citation | British journal of cancer, 2018, 119 (11), pp. 1332 - 1338 | |
dc.identifier.issn | 0007-0920 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3065 | |
dc.identifier.eissn | 1532-1827 | |
dc.identifier.doi | 10.1038/s41416-018-0319-z | |
dc.description.abstract | Background The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus the usually given 6 months (6 M) of adjuvant chemotherapy in colorectal cancer.Methods In total, 6088 patients with fully resected high-risk stage II or stage III colorectal cancer were randomised and followed up for 3-8 years. The within-trial cost-effectiveness analysis from a UK health-care perspective is presented using the resource use data, quality of life (EQ-5D-3L), time on treatment (ToT), disease-free survival after treatment (DFS) and overall survival (OS) data. Quality-adjusted partitioned survival analysis and Kaplan-Meier Sample Average Estimator estimated QALYs and costs. Probabilistic sensitivity and subgroup analysis was undertaken.Results The 3 M arm is less costly (-£4881; 95% CI: -£6269; -£3492) and entails (non-significant) QALY gains (0.08; 95% CI: -0.086; 0.230) due to a better significant quality of life. The net monetary benefit was significantly higher in 3 M under a wide range of monetary values of a QALY. The subgroup analysis found similar results for patients in the CAPOX regimen. However, for the FOLFOX regimen, 3 M had lower QALYs than 6 M (not statistically significant).Conclusions Overall, 3 M dominates 6 M with no significant detrimental impact on QALYs. The results provide the economic case that a 3 M treatment strategy should be considered a new standard of care. | |
dc.format | Print-Electronic | |
dc.format.extent | 1332 - 1338 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Colorectal Neoplasms | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Chemotherapy, Adjuvant | |
dc.subject | Survival Analysis | |
dc.subject | Quality-Adjusted Life Years | |
dc.subject | Quality of Life | |
dc.subject | Cost-Benefit Analysis | |
dc.subject | Oxaliplatin | |
dc.title | SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-10-09 | |
rioxxterms.versionofrecord | 10.1038/s41416-018-0319-z | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-11-13 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | British journal of cancer | |
pubs.issue | 11 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine (RMH Smith Cunningham)/Medicine (RMH Smith Cunningham) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 119 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicine (RMH Smith Cunningham) | en_US |
dc.contributor.icrauthor | Cunningham, David | |